Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease-Reference-Cited by-同舟云学术

Plasma Triglycerides and Cardiovascular Events in the Treating to New Targets and Incremental Decrease in End-Points Through Aggressive Lipid Lowering Trials of Statins in Patients With Coronary Artery Disease

Published:2009-08 Issue:4 Volume:104 Page:459-463
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Faergeman Ole,Holme Ingar,Fayyad Rana,Bhatia Sonal,Grundy Scott M.,Kastelein John J.P.,LaRosa John C.,Larsen Mogens Lytken,Lindahl Christina,Olsson Anders G.,Tikkanen Matti J.,Waters David D.,Pedersen Terje R.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference20 articles.

1. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial;Pedersen;JAMA,2005

2. Intensive lipid lowering with atorvastatin in patients with stable coronary disease;LaRosa;N Engl J Med,2005

3. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study;Pedersen;Am J Cardiol,2004

4. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?;Waters;Am J Cardiol,2004

5. Enzymatic determination of total serum cholesterol;Allain;Clin Chem,1974

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia;Frontiers in Cardiovascular Medicine;2024-08-07

2. Construction and Validation of a Predictive Model for Coronary Artery Disease Using Extreme Gradient Boosting;Journal of Inflammation Research;2024-07

3. Low Levels of IgM Recognizing 4-Hydroxy-2-Nonenal-Modified Apolipoprotein A-I Peptide and Its Association with the Severity of Coronary Artery Disease in Taiwanese Patients;Current Issues in Molecular Biology;2024-06-20

4. Managing hypertriglyceridemia for cardiovascular disease prevention: Lessons from the PROMINENT trial;European Journal of Clinical Investigation;2024-04-25

5. Triglycerides, Triglyceride-Rich Lipoproteins, and High-Density Lipoprotein in Coronary Heart Disease Risk Assessment;Clinical Lipidology;2024